    <script type="text/javascript">

            // used in ui component
        window.pnrApplicationSettings = {
                Application:"pnr",
                SelectedLocale: 'en-US',
                PnrHostUrl: 'https://www.globenewswire.com',
                IsAuthenticated: 'False' === "True" ? true : false,
                ContextUser: '',
                ApplicationUrl: 'https://www.globenewswire.com',
                PageContext: '',
                SubscriptionId: 0,
                SubscriptionName: '',
                ArticleLogoUrl: '',
                ArticleHeadline: '',
                IsMobileVersion: 'False' === "True" ? true : false,
                HideLanguageSelection : false,
                NewsSearchHeading: '',
                ArticleMediaAttachments: [],
                AuthSessionExpirationMinutes: '0',
                AppLogoUrl: 'https://www.globenewswire.com/content/logo/color.svg',
                ReaderForgotPasswordUrl: 'https://pnrlogin.globenewswire.com/en/reset/confirmresetpassword',
                ReaderRegisterUrl: 'https://pnrlogin.globenewswire.com/en/register',
                IsQuickSignInEnabled: true,
                ReaderAccountBaseUrl: 'https://pnrlogin.globenewswire.com',
                articleSideBarSettings:{},
                SiteSupportedLanguages: 'en,fr,de',
                CookieConsentSettings: {
                   IsCookieConsentV2Enabled: true,
                   OneTrustEndpoint: 'https://cdn.cookielaw.org/scripttemplates/otSDKStub.js',
                   OneTrustDomain: '93ab55d0-5227-4b5f-9baa-7c0805ac9eec',
                },
                HideOrganizationSearch: false,
                SearchBasePath: '/search/',
                GoogleClientId: '747241285181-l5skhv8icjefl651ehg7ps4eif8kpqgi.apps.googleusercontent.com',
                GoogleSsoEnabled: true,
                ArticleLanguage: "",
                LinkedInSsoEnabled: false,
                LinkedInVersion: '',
				ClaimStatus: null,
				HideQuickSignInLogin:false,
                SessionId: '',
            };
    </script>
<!DOCTYPE HTML>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en">

<head>
    <base href="https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html" />
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />

            <script type="text/javascript" src="https://cdn.cookielaw.org/consent/93ab55d0-5227-4b5f-9baa-7c0805ac9eec/OtAutoBlock.js"></script>


    <title>BioAge Labs Reports First Quarter 2025 Financial Results</title>
    


<!-- Search Engine Friendly Metadata  -->
<meta name="author" content="BioAge Labs, Inc." />
<meta name="keywords" content="Nasdaq:BIOA, BioAge Labs, Inc." />
<meta name="description" content="Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic..." />
<meta name="title" content="BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business&#160;Updates" />
<meta name="ticker" content="" />
<meta name="DC.date.issued" content="5/6/2025" />
<!-- Google site verification meta tag -->
<meta name="google-site-verification" content="TPh-fYpDjXZUz98ciWasVb52qbvctqomC6zZc8vuUPU" />
<!-- Google Syndication source  -->
<link name="syndication-source" href="https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html" />
<meta name="original-source" content="https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html" />
<!-- Twitter Cards -->
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="globenewswire" />
<meta name="twitter:title" content="BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business&#160;Updates" />
<meta name="twitter:description" content="Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic..." />
<!-- <meta name="twitter:creator" content="??????" />  -->
<!-- Open Graph-->
<meta property="og:title" content="BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business&#160;Updates" />
<meta property="og:type" content="article" />

        <meta name="twitter:image" content="https://ml.globenewswire.com/Resource/Download/d6df9eb5-87f7-4e2e-b503-8a7d8651428e"/>
        <meta property="og:image" content="https://ml.globenewswire.com/Resource/Download/d6df9eb5-87f7-4e2e-b503-8a7d8651428e"/>

<meta property="og:url" content="https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html" />
<meta property="og:description" content="Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic..." />
<meta property="og:article:published_time" content="5/6/2025 8:30:00 PM" />
<meta property="og:article:author " content="BioAge Labs, Inc." />
<meta property="og:article:tag" content="BioAge Labs, Inc., " />
<meta property="og:locale" content="en_US" />
<meta property="og:site_name" content="GlobeNewswire News Room" />


    <meta http-equiv="content-language" content="en-us">
    <link rel="shortcut icon" href="/Content/logo/favicon.ico" type="image/x-icon" />

    <link rel="preload" as="style" href="/Content/css/bootstrap.min.css" onload="this.rel='stylesheet'" />
    <link rel="preload" as="style" href="/bundles/pnr-global-styles-v2?v=-p2joBtS-kBJ-pul5aXWN1If_byQqiZ8Z2wjD0sTZMQ1" onload="this.rel='stylesheet'" />
    <link rel="preload" as="style" href="/bundles/react-styles?v=W7CYwdegYVesX-sZs8VC5guLT6TocNXnZ4xJTxY-XLg1" onload="this.rel='stylesheet'" />
    <link rel="preload" as="style" href="/home/assests/styles/global-override.css" onload="this.rel='stylesheet'" />
    <link href="/bundles/react-styles?v=W7CYwdegYVesX-sZs8VC5guLT6TocNXnZ4xJTxY-XLg1" rel="stylesheet"/>


    <script src="/Scripts/stickyfill.min.js" defer async></script>

        <link rel="canonical" href="https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html" />
                <link rel="alternate" href="https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html" hreflang="x-default" />
                <link rel="alternate" href="https://www.globenewswire.com/fr/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html" hreflang="fr" />
                <link rel="alternate" href="https://www.globenewswire.com/de/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html" hreflang="de" />
<script type="text/javascript" defer src="/bundles/layout-jquery-scripts?v=TXkXsX7p7r9-AnnjDqFdUGhnEN2-r8TpYAaGbshNq4s1"></script>
        <link rel="preload" href="/bundles/react-scripts?v=MqOfEk5vGlRc1cPxLQ7WVroHOcEbh1JSMWPfmpZf4MY1" as="script">

    <script type="text/javascript">
        window.enableInlineImageZoom = false;
        var fsEnableInlineImageZoom = 'True';
        if (fsEnableInlineImageZoom && fsEnableInlineImageZoom.trim().toLowerCase() === 'true')
        {
            window.enableInlineImageZoom = true;
        }

        window.quoteCarouselSettings = {
            isEnabled: 'False' === 'True' ? true : false,
            documentQuotes: '',
            releaseYear: '2025',
        };



    </script>
    <script src="/bundles/article-details-scripts?v=lJebJ5FCZXMVXTNP99IRRTLpqSSwCPwf50HA0qy4tnY1"></script>


<input name="__RequestVerificationToken" type="hidden" value="ONbXIuuH4Zr53E186QUg5Kj0QRXUdVN4_SAwgXmarY9oluhUTPTq6w2GLtaVd8kkPxh95stbjmtaFR560kOkWr4k7ks1" />
    <script type="application/ld+json">
        {"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","id":"https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html"},"Headline":"BioAge Labs Reports First Quarter 2025 Financial Results and Provides BusinessÂ Updates","DatePublished":"5/6/2025","DateModified":"5/6/2025","inLanguage":"en","author":{"@type":"Person","name":"BioAge Labs, Inc."},"publisher":{"@type":"Organization","name":"BioAge Labs, Inc.","logo":{"@type":"ImageObject","url":"http://www.globenewswire.com/Attachment/LogoDisplay/1291388?filename=1291388.png&size=1"}},"Description":"Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic......"}
    </script>



    
    <link href="/bundles/article-details-styles?v=o5D9p26SgW1t42Xux7K6-yxvairBxRIiUUFOGCEamog1" rel="stylesheet"/>



            <!-- Google Analytics -->
            <script async src="https://www.googletagmanager.com/gtag/js?id=G-ERWPGTJ5X8"></script>
            <script type="text/javascript">
              window.dataLayer = window.dataLayer || [];
              function gtag(){dataLayer.push(arguments);}
              gtag('js', new Date());

              gtag('config', 'G-ERWPGTJ5X8');

              window.EventsCaptureEnabled = 'False' === 'True';
            </script>
            <!-- Google Tag Manager -->
            <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                    new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
                j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
                    'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KTB664ZR');
            </script>

    <script src="/bundles/global-shared-scripts?v=PmHtybmvVT6FMOPUIYivGHk7z7LLNR6HSEM85AQPjJo1"></script>

</head>
<body id="app-body-container">
    <!-- Google Tag Manager (noscript) -->
    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KTB664ZR" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <div role="main">
        <a href="#maincontainer" class="skip-link btn btn-primary text-uppercase">Accessibility: Skip TopNav</a>
        <!--Start header -->
        <div id="pnr-global-site-header-section" style="min-height: 85px">
        </div>
        <!--End header-->
        <!-- Start Body -->
        <div class="pnr-body-container" id="maincontainer" tabindex="-1">
            





<script type="text/javascript">
       var articleSideBarEnabled = false;
       var fsArticleSideBarEnabled = 'True';
       if (fsArticleSideBarEnabled && fsArticleSideBarEnabled.trim().toLowerCase() === 'true')
       {
          articleSideBarEnabled = true;
    }
</script>

<div class="main-container container-overwrite p-0 d-flex" id="container-article" itemscope itemtype="http://schema.org/NewsArticle">

    <div class="main-container-content ">
        <meta itemprop="wordCount" content="0" />
        <meta itemprop="inLanguage" content="en" />
        <meta itemprop="description" name="description" content="Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic..." />
        <meta itemprop="dateModified" content="5/6/2025" />
        <meta itemscope itemprop="mainEntityOfPage" itemType="https://schema.org/WebPage" itemid="https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html" />

        <div class="main-header-container ">






    <div class="carousel-container" id="article-logo-carousel">
    </div>
<script type="text/javascript">

    window.pnrApplicationSettings.PageContext = 'article-page';
    window.articlesSecondaryLogos = null;
        window.articlesSecondaryLogos = JSON.parse('[{\"Title\":\"Bioage_Dark_Logo_White_BG 500x500.png\",\"Caption\":null,\"altText\":\"Bioage_Dark_Logo_White_BG 500x500.png\",\"LogoUrl\":\"https://ml.globenewswire.com/Resource/Download/d6df9eb5-87f7-4e2e-b503-8a7d8651428e\",\"SourceAlias\":null,\"IsPrimaryLogo\":true,\"ShowDownloadLink\":false}]');


    try {
        window.pnrApplicationSettings.ArticleLogoUrl = 'https://ml.globenewswire.com/Resource/Download/d6df9eb5-87f7-4e2e-b503-8a7d8651428e?size=3';
    } catch (ex) {
        console.log(e);
    }
</script>


            <h1 class="article-headline" itemprop="headline" >BioAge Labs Reports First Quarter 2025 Financial Results and Provides BusinessÂ Updates</h1>




<p class="article-published-source">


    <span class="d-flex justify-content-start">
        <span class="article-published" itemprop="datePublished">
            <time datetime="5/6/2025 8:30:00 PM">May 06, 2025 16:30 ET</time>
        </span>

        <span class="article-source" itemprop="sourceOrganization" itemscope itemtype="http://schema.org/Organization">
            <span>&nbsp;</span>| Source:
            <span>

                <a href="/en/search/organization/BioAge%2520LabsÎ´%2520Inc&#167;" itemprop="name">BioAge Labs, Inc.</a>
            </span>
                <meta itemprop="logo" url="https://ml.globenewswire.com/Resource/Download/d6df9eb5-87f7-4e2e-b503-8a7d8651428e?size=2" alt="Company Name Logo" />

        </span>
    </span>

    <span id="pnr-global-follow-button" class="pnr-follow-button-width-height"></span>

    <span itemprop="author copyrightHolder" style="display: none;">BioAge Labs, Inc.</span>

    

</p>

<script type="text/javascript">
    window.pnrApplicationSettings.articleSideBarSettings.orgDetails = {
            location : '',
            name : "BioAge Labs, Inc.",
            website : '',
            industryName: 'Pharmaceuticals \u0026 Biotechnology',
            boilerplate: '',
            isCompanyProfileSectionVisible: 'True' === 'True' ? true : false,
            ceo: '',
            numberOfEmployees: '',
            revenue: '',
            netIncome: '',
    }

    window.pnrApplicationSettings.articleSideBarSettings.socialSettings = {
        facebookHandle: '',
        twitterHandle: '',
        linkedInHandle: '',
        youtubeHandle: '',
        vimeoHandle: '',
        tiktokHandle: '',
        instagramHandle: '',
        isSocialHandlersSectionVisible: 'True' === 'True' ? true : false,
        isSocialTimeLineSectionStatus: {
            twitterTimeLineSectionVisible : false,
        },
        isTwitterTimeLineEnabled:'False' === 'True' ? true : false,
    }
</script>

        </div>
        <hr />
        <div class="main-scroll-container" style="display: block; position: relative; margin-top: 4rem; min-height: 300px;">
            <div id="pnr-global-social-media-sidebar-section" style="display: block; position: absolute; height: 100%;"></div>
            <div class="main-body-container article-body "  id="main-body-container" itemprop="articleBody">
<ul><li style="text-align:justify;"><em>Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25</em><br /></li><li style="text-align:justify;"><em>New strategic collaboration with Lilly ExploR&amp;D expands therapeutic approach to novel metabolic aging targets</em><br /></li><li style="text-align:justify;"><em>Progression of preclinical next-generation APJ agonists for obesity</em><br /></li></ul>    <p align="justify">RICHMOND, Calif., May  06, 2025  (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", âthe Companyâ), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided business updates and reported its first quarter 2025 financial results.</p>    <p align="justify">âThe first quarter of 2025 was marked by strategic execution as we advanced our focused pipeline," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. "We've made significant progress with BGE-102, our brain-penetrant NLRP3 inhibitor, and are on track with IND-enabling studies to bring this potential best-in-class compound to the clinic this year, with initial Phase 1 data expected before year-end. Our new collaboration with Lilly expands our therapeutic capabilities into antibodies while validating our platform-driven approach to targeting the biology of aging. Meanwhile, both our novel APJ agonist program and our partnership with Novartis continue to make meaningful progress. With these scientific advancements and our strong financial position, we're well-positioned to deliver on our mission to leverage the biology of aging to develop transformative treatments for metabolic diseases."</p>    <p align="justify"><strong>First Quarter 2025 Business Highlights </strong></p>    <p align="justify"><em>NLRP3 program development</em>Â </p>    <ul type="disc"><li style="margin-top:12pt; margin-bottom:12pt; text-align:justify;">In January 2025, BioAge nominated BGE-102, a novel, orally available small-molecule NLRP3 inhibitor, as its lead development candidate for obesity. The compound shows potential best-in-class potency and brain penetration, and can target diseases driven by neuroinflammation including metabolic conditions and obesity. In preclinical studies, NLRP3 inhibition has demonstrated significant weight loss potential. IND-enabling studies are currently underway, with initial Phase 1 data anticipated in the second half of 2025.<br /><br /></li></ul>    <p align="justify"><em>Strategic collaborations</em></p>    <ul><li style="text-align:justify;">In January 2025, BioAge announced a strategic collaboration with Lilly ExploR&amp;D to develop two therapeutic antibodies targeting novel metabolic aging targets identified through BioAge's discovery platform.<br /><br /></li></ul>    <p align="justify"><em>Pipeline advancement</em></p>    <ul><li style="text-align:justify;">The Company continues to advance its portfolio of novel, structurally differentiated APJ agonists for obesity and related metabolic conditions, with the goal of nominating a development candidate by the end of 2025. BioAge's multi-year research collaboration with Novartis, focused on discovering novel therapeutic targets at the intersection of aging biology and exercise physiology, continues to make meaningful progress.<br /><br /></li></ul>    <p align="justify"><strong>First Quarter 2025 Financial Results</strong></p>    <p align="justify">Research and development expenses were $11.1 million for the quarter ended March 31, 2025, compared to $9.3 million for the same period in 2024. The $1.8 million increase in research and development expenses was primarily attributable to a $2.7 million increase in direct costs related to other programs as BioAge focused its research and development activities on IND-enabling activities for BGE-102.</p>    <p align="justify">General and administrative expenses were $6.8 million for the quarter ended March 31, 2025,, compared to $3.5 million for the same period in 2024. The $3.3 million increase was primarily attributable to a $2.0 million increase in personnel-related expenses, which was largely attributable to increased stock-based compensation expense associated with option grants issued to employees, executives, board members and advisors. Additionally, contributing to the increase was a $0.5 million increase in legal fees, and a $0.4 million increase in taxes and insurance, primarily related to our public-company director and officer insurance policy.</p>    <p align="justify">Net loss was $12.9 million for the quarter ended March 31, 2025, or $0.36 per weighted-average common share outstanding, basic and diluted, compared to a net loss of $13.0 million, or $7.76 per weighted-average common share outstanding, basic and diluted, for the same period in 2024.</p>    <p align="justify">As of March 31, 2025, BioAge had approximately $335.1 million in cash, cash equivalents, and marketable securities. Based on our current operating plan, BioAge estimates that existing cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenses through 2029.</p>    <p align="justify"><strong>About BioAge Labs, Inc.</strong></p>    <p align="justify">BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The companyâs pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. BioAgeâs additional preclinical programs, which leverage insights from the Companyâs proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.</p>    <p align="justify"><strong>Forward-looking statements</strong></p>    <p align="justify">This press release contains âforward-looking statementsâ within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our plans to develop and commercialize our product candidates, the timing and results of our planned clinical trials, risks associated with clinical trials, including our ability to adequately manage clinical activities, the timing of and our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates, the sufficiency of our cash and cash equivalents, and general economic, industry and market conditions. These forward-looking statements may be accompanied by such words as âaim,â âanticipate,â âbelieve,â âcould,â âestimate,â âexpect,â âforecast,â âgoal,â âintend,â âmay,â âmight,â âplan,â âpotential,â âpossible,â âwill,â âwould,â and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions, including due to the imposition of tariffs and other trade barriers; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; changes in or failure to comply with legal and regulatory requirements, including shifting priorities within the U.S. Food and Drug Administration; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading âRisk Factorsâ included in BioAgeâs Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on May 6, 2025, and BioAgeâs other filings with the SEC filed from time to time. BioAge undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p>    <p align="justify"><strong>Contacts</strong><br />PR: Chris Patil, media@bioagelabs.com <br />IR: Dov Goldstein, ir@bioagelabs.com <br />Partnering: partnering@bioagelabs.com <br />Web: https://bioagelabs.com</p>  <table align="center" style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td colspan="8" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>BIOAGE LABS, INC.</strong><br /><strong>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</strong><br /><strong>(in thousands, except share and per share information)</strong></td></tr><tr><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Three Months Ended</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td colspan="6" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>MarchÂ 31,</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2025</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; vertical-align: bottom ; ">Â </td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="max-width:75%; width:75%; min-width:75%;;vertical-align: top ; ">Collaboration revenue</td><td style="max-width:2%; width:2%; min-width:2%;;border-top: solid black 1pt ; vertical-align: bottom ; ">$</td><td style="max-width:9%; width:9%; min-width:9%;;border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,451</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">Â </td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">Â </td><td style="max-width:2%; width:2%; min-width:2%;;border-top: solid black 1pt ; vertical-align: bottom ; ">$</td><td style="max-width:9%; width:9%; min-width:9%;;border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">â</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Operating expenses:</td><td colspan="2" style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">Research and development</td><td style="vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">11,109</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">9,321</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">General and administrative</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">6,788</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3,492</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; vertical-align: top ; ">Total operating expenses</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">17,897</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">12,813</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Loss from operations</td><td style="border-top: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(16,446</td><td style="vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(12,813</td><td style="vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: top ; ">Other income (expense)</td><td colspan="2" style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; vertical-align: top ; ">Interest expense</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(255</td><td style="vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1,217</td><td style="vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; vertical-align: top ; ">Interest and other income (expense), net</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3,714</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,296</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; vertical-align: top ; ">Gain (loss) from changes in fair value of warrants</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">59</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(8</td><td style="vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; vertical-align: top ; ">Loss on extinguishment of debt</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">â</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(250</td><td style="vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: top ; ">Total other income (expense), net</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3,518</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(179</td><td style="vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: top ; ">Net loss</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; vertical-align: bottom ; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(12,928</td><td style="vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; vertical-align: bottom ; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(12,992</td><td style="vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: top ; ">Net loss per share attributable to common stockholders, basic and diluted</td><td style="border-top: double black 3pt ; border-bottom: double black 3pt ; vertical-align: bottom ; ">$</td><td style="border-top: double black 3pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(0.36</td><td style="vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: double black 3pt ; border-bottom: double black 3pt ; vertical-align: bottom ; ">$</td><td style="border-top: double black 3pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(7.76</td><td style="vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: top ; ">Weighted-average common shares outstanding, basic and dilutive</td><td style="border-top: double black 3pt ; border-bottom: double black 3pt ; vertical-align: bottom ; ">Â </td><td style="border-top: double black 3pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">35,850,037</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: double black 3pt ; border-bottom: double black 3pt ; vertical-align: bottom ; ">Â </td><td style="border-top: double black 3pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,673,472</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Comprehensive loss:</td><td colspan="2" style="border-top: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="border-top: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">Net loss</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(12,928</td><td style="vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(12,992</td><td style="vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">Other comprehensive income:</td><td colspan="2" style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; vertical-align: top ; ">Unrealized holding gains on available-for-sale investments</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">29</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">â</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 20.0px; vertical-align: top ; ">Foreign currency translation adjustment</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(10</td><td style="vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">21</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: top ; ">Total other comprehensive income:</td><td style="border-top: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">19</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">21</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Total comprehensive loss</td><td style="border-bottom: double black 3pt ; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(12,909</td><td style="vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">Â </td><td style="border-bottom: double black 3pt ; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(12,971</td><td style="vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: top ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td></tr></table>  <p align="justify"><br /></p>  <table align="center" style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td colspan="2" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td colspan="8" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>BIOAGE LABS, INC.</strong><br /><strong>Unaudited Condensed Consolidated Balance Sheets</strong><br /><strong>(in thousands, except share and per share information)</strong></td></tr><tr><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td colspan="2" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td colspan="2" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>MarchÂ 31,</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>DecemberÂ 31,</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td colspan="2" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2025</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; "><strong>Assets</strong></td><td colspan="2" style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Current Assets:</td><td colspan="2" style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="max-width:75%; width:75%; min-width:75%;;vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">Cash and cash equivalents</td><td style="max-width:2%; width:2%; min-width:2%;;text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="max-width:9%; width:9%; min-width:9%;;text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">257,486</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">Â </td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">Â </td><td style="max-width:2%; width:2%; min-width:2%;;text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="max-width:9%; width:9%; min-width:9%;;text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">354,349</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">Marketable securities, current</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">63,032</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">â</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">Accounts receivable</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">361</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">â</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">Prepaid expenses and other current assets</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3,934</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,754</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: top ; ">Total current assets</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">324,813</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">357,103</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Investments</td><td style="border-top: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">100</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">100</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Marketable securities</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">14,559</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">â</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Property and equipment, net</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">929</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">591</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Operating lease right-of-use assets, net</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3,201</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">200</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Other assets</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">239</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">240</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Total assets</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">343,841</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">358,234</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; "><strong>Liabilities</strong></td><td colspan="2" style="border-top: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="border-top: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Current Liabilities:</td><td colspan="2" style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">Accounts payable</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3,989</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,996</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">Accrued expenses and other current liabilities</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4,866</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">11,751</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">Term loan, current</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">6,000</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">6,000</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">Operating lease liabilities, current</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">700</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">202</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; vertical-align: top ; ">Deferred revenue, current</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">8,183</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">7,826</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: top ; ">Total current liabilities</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">23,738</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">27,775</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Deferred revenue</td><td style="border-top: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3,227</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4,674</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Term loan</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,056</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,502</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Warrant liability</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">97</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">156</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Operating lease liabilities</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,556</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">â</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 25.0px; vertical-align: top ; ">Total liabilities</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">30,674</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">35,107</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: top ; ">Commitments and Contingencies (Note 8)</td><td colspan="2" style="border-top: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="border-top: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; "><strong>Stockholdersâ Equity</strong></td><td colspan="2" style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td colspan="2" style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Preferred stock, $0.00001 par value; 10,000,000 shares authorized as of MarchÂ 31, 2025 and December 31, 2024; no shares issued or outstanding as of MarchÂ 31, 2025 and December 31, 2024</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">â</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">â</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Common stock, $0.00001 par value; 500,000,000 shares authorized as of MarchÂ 31, 2025 and DecemberÂ 31, 2024; 35,850,037 shares issued and outstanding as of MarchÂ 31, 2025 and DecemberÂ 31, 2024</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">â</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">â</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Additional paid-in-capital</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">578,642</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">575,693</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Accumulated other comprehensive income</td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">264</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">245</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Accumulated deficit</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(265,739</td><td style="vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(252,811</td><td style="vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: top ; ">Total stockholdersâ equity</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">313,167</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">323,127</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Total liabilities and stockholdersâ equity</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">343,841</td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">358,234</td><td style="vertical-align: bottom ; ">Â </td></tr><tr><td style="vertical-align: top ; ">Â </td><td style="border-top: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; vertical-align: bottom ; ">Â </td><td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">Â </td><td style="vertical-align: bottom ; ">Â </td></tr></table> <br/><img alt="" src='https://ml.globenewswire.com/media/MTMwOTJmOGEtNTlhYS00ZmNmLTk4OTgtMWUyNWFlODk2ZmE1LTEyMTQwMzMtMjAyNS0wNS0wNi1lbg==/tiny/BioAge-Labs-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />
            </div>






<script type="text/javascript">


</script>


<!-- Contact -->


        </div>

        <meta itemprop="provider" content="âGlobeNewswireâ" />
        <meta itemprop="isFamilyFriendly" content="true" />
        <meta itemprop="copyrightYear" content="2025" />
    </div>
        <div class="company-profile-content" id="article-side-bar" style="position: relative; width: 20%; padding: 50px 32px;"></div>
</div>


<script type="text/javascript">
    window.setTimeout(() => {
        try {
            autoFitImages('.featuredNewsH', { debug: false });
        } catch (error) {
            console.error('Error in autoFitImages:', error);
        }
    }, 100); 
</script>
        <div class="container-fluid">
            <div class="custom-container">
                <div class="row">
                    <div class="col-xl-12">
                        <h2>Recommended Reading</h2>
                        <div class="featuredNewsH">
                            <ul>
                                        <li class="row">
                                            <div class="col-lg-8">
                                                <div class="featuredNewsLink">
                                                    <div class="date-source">
                                                        <span>March 20, 2025 16:30 ET</span>
                                                        <span>|</span>
                                                        <span>Source: <a href="/en/search/organization/BioAge%2520LabsÎ´%2520Inc&#167;" class="sourceLink">BioAge Labs, Inc.</a></span>
                                                    </div>
                                                    <div class="featuredMainLink">
                                                        <a href="https://www.globenewswire.com/news-release/2025/03/20/3046733/0/en/BioAge-Labs-Reports-Full-Year-2024-Financial-Results-and-Provides-Business-Updates-from-the-Fourth-Quarter-of-2024.html">
                                                            BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
                                                        </a>
                                                    </div>
                                                    <div class="featuredNewsTxt">
                                                        <p>
                                                            Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25  Progression of preclinical next-generation APJ agonists for obesity  New platform partnerships...
                                                        </p>
                                                        <a href="https://www.globenewswire.com/news-release/2025/03/20/3046733/0/en/BioAge-Labs-Reports-Full-Year-2024-Financial-Results-and-Provides-Business-Updates-from-the-Fourth-Quarter-of-2024.html" class="btn-small-charcoal mt-2 mr-2 " target="_self">Read More</a>
                                                    </div>
                                                </div> <!-- newsLink -->
                                            </div> <!-- col-lg-8 -->

                                            <div class="col-lg-4 justify-content-center">
                                                <div class="featuredNewsImg" title="BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024">
                                                    <img src="https://ml.globenewswire.com/Resource/Download/d6df9eb5-87f7-4e2e-b503-8a7d8651428e?size=3" alt="BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024">
                                                </div> <!-- featuredNewsImg -->
                                            </div> <!-- col-lg-4 -->

                                        </li>
                                        <!-- row -->
                                        <li class="row">
                                            <div class="col-lg-8">
                                                <div class="featuredNewsLink">
                                                    <div class="date-source">
                                                        <span>February 20, 2025 16:30 ET</span>
                                                        <span>|</span>
                                                        <span>Source: <a href="/en/search/organization/BioAge%2520LabsÎ´%2520Inc&#167;" class="sourceLink">BioAge Labs, Inc.</a></span>
                                                    </div>
                                                    <div class="featuredMainLink">
                                                        <a href="https://www.globenewswire.com/news-release/2025/02/20/3030118/0/en/BioAge-Labs-to-Participate-in-TD-Cowen-s-45th-Annual-Health-Care-Conference.html">
                                                            BioAge Labs to Participate in TD Cowen&#39;s 45th Annual Health Care Conference
                                                        </a>
                                                    </div>
                                                    <div class="featuredNewsTxt">
                                                        <p>
                                                            RICHMOND, Calif., Feb.  20, 2025  (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (âBioAgeâ, âthe Companyâ), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
                                                        </p>
                                                        <a href="https://www.globenewswire.com/news-release/2025/02/20/3030118/0/en/BioAge-Labs-to-Participate-in-TD-Cowen-s-45th-Annual-Health-Care-Conference.html" class="btn-small-charcoal mt-2 mr-2 " target="_self">Read More</a>
                                                    </div>
                                                </div> <!-- newsLink -->
                                            </div> <!-- col-lg-8 -->

                                            <div class="col-lg-4 justify-content-center">
                                                <div class="featuredNewsImg" title="BioAge Labs to Participate in TD Cowen&#39;s 45th Annual Health Care Conference">
                                                    <img src="https://ml.globenewswire.com/Resource/Download/d6df9eb5-87f7-4e2e-b503-8a7d8651428e?size=3" alt="BioAge Labs to Participate in TD Cowen&#39;s 45th Annual Health Care Conference">
                                                </div> <!-- featuredNewsImg -->
                                            </div> <!-- col-lg-4 -->

                                        </li>
                                        <!-- row -->

                            </ul>
                        </div> <!-- recentNewsH -->
                    </div> <!-- col-xl-12 -->
                </div> <!-- row -->
            </div> <!-- custom-container -->
        </div>
        <!-- container-fluid -->



<div class="container-fluid">
    <div id="pnr-global-card-explore-view" class="custom-container"></div>
</div>
<div id="attachment-render-section"></div>
<div id="large-table-viewer"></div>

        <input type="hidden" value="06-05-2025 08:31:14 UTC" data-format="DD-MM-YYYY HH:MM:SS" data-context="article" data-type="index" />
        <input type="hidden" value="06-05-2025 08:31:14 UTC" data-format="DD-MM-YYYY HH:MM:SS" data-context="body" data-type="index" />
    <input type="hidden" name="data-source" value="OS"/>


<script type="text/javascript">

    window.pnrApplicationSettings.PageContext = 'article-page';

    try {
        window.pnrApplicationSettings.ArticleHeadline = 'BioAge Labs Reports First Quarter 2025 Financial Results and Provides BusinessÂ Updates';
    } catch (ex) {
        console.log(ex);
    }
    window.pnrApplicationSettings.IsAuthenticated = false;
    window.analyticsTrackingId = '13092f8a-59aa-4fcf-9898-1e25ae896fa5';

    window.cardExplore = {
        id:"pnr-global-card-explore-view",
        ExploreView:{
            ApiUrl: "/api/article/explore/en/False",
            IsHorizontalView : true
        }
    };



    window.ZoomOutTitle = 'Expand';
    window.combinedMediaPortal = {
        followButtonElementId:"pnr-global-follow-button",
        socialMediaSideBarElementId:"pnr-global-social-media-sidebar-section",
        followFormModel: {
            ApiUrl:'/api/subscribe/follow-organization',
            ContextOrgId:61133,
            OrgName:'BioAge Labs, Inc.'
        },
        socialShareModel: JSON.parse('{\"SocialItemData\":{\"Url\":\"https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html\",\"Title\":\"BioAge Labs Reports First Quarter 2025 Financial Results and Provides BusinessÂ Updates\",\"Body\":\"Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic collaboration with Lilly ExploR\\u0026amp;D expands...\"},\"AdditionalItems\":[{\"Key\":\"printedcopy\",\"Label\":\"Print\",\"Url\":\"https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html?print=1\",\"Track\":true},{\"Key\":\"downloadPdf\",\"Label\":\"Download PDF\",\"Url\":\"https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html?pdf=1\",\"Track\":true},{\"Key\":\"rss\",\"Label\":\"Subscribe via RSS\",\"Url\":\"/rssfeed/organization/ftcZoyGJ1Y2C_juqa1nPZA==\",\"Track\":true},{\"Key\":\"atom\",\"Label\":\"Subscribe via ATOM\",\"Url\":\"/atomfeed/organization/ftcZoyGJ1Y2C_juqa1nPZA==\",\"Track\":true},{\"Key\":\"js-widget\",\"Label\":\"Javascript\",\"Url\":\"https://www.globenewswire.com/JSWidget/organization/ZyZYimLyjaCnrdF2tNFZlA%3d%3d\",\"Track\":false}],\"BasicModel\":false,\"ShowPintrest\":false}')
    }

    window.pnrApplicationSettings.NavBarScrollHeight = 300;
    window.pnrApplicationSettings.Version = 'dark';
    window.pnrApplicationSettings.articleSideBarSettings.pressReleaseActions = JSON.parse('{\"SocialItemData\":{\"Url\":\"https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html\",\"Title\":\"BioAge Labs Reports First Quarter 2025 Financial Results and Provides BusinessÂ Updates\",\"Body\":\"Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic collaboration with Lilly ExploR\\u0026amp;D expands...\"},\"AdditionalItems\":[{\"Key\":\"printedcopy\",\"Label\":\"Print\",\"Url\":\"https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html?print=1\",\"Track\":true},{\"Key\":\"downloadPdf\",\"Label\":\"Download PDF\",\"Url\":\"https://www.globenewswire.com/news-release/2025/05/06/3075592/0/en/BioAge-Labs-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html?pdf=1\",\"Track\":true},{\"Key\":\"rss\",\"Label\":\"Subscribe via RSS\",\"Url\":\"/rssfeed/organization/ftcZoyGJ1Y2C_juqa1nPZA==\",\"Track\":true},{\"Key\":\"atom\",\"Label\":\"Subscribe via ATOM\",\"Url\":\"/atomfeed/organization/ftcZoyGJ1Y2C_juqa1nPZA==\",\"Track\":true},{\"Key\":\"js-widget\",\"Label\":\"Javascript\",\"Url\":\"https://www.globenewswire.com/JSWidget/organization/ZyZYimLyjaCnrdF2tNFZlA%3d%3d\",\"Track\":false}],\"BasicModel\":false,\"ShowPintrest\":false}');
    window.pnrApplicationSettings.articleSideBarSettings.isEnabled = true;
    window.pnrApplicationSettings.articleSideBarSettings.releaseSummary = '';
    window.pnrApplicationSettings.articleSideBarSettings.isPreviewOnlyMode = false;
    window.pnrApplicationSettings.ArticleLanguage = "en";

</script>

        </div>
        <!-- End Body -->
        <!--Start footer -->
        <div id="pnr-global-site-footer-section" class="home-page-footer"></div>
        <!--End footer-->

        <div id="cookies-consent" style="position: fixed"></div>

        <script>
            var preloadedScript = document.createElement("script");
            preloadedScript.src = "/bundles/react-scripts?v=MqOfEk5vGlRc1cPxLQ7WVroHOcEbh1JSMWPfmpZf4MY1";
            document.head.appendChild(preloadedScript);
        </script>
        <noscript>
            <script src="/bundles/react-scripts?v=MqOfEk5vGlRc1cPxLQ7WVroHOcEbh1JSMWPfmpZf4MY1"></script>

        </noscript>
    </div>
    <div id="quick-reader-sign-container"></div>
</body>
</html>
